Management of Apixaban Before Right Heart Catheterization

Introduction to Apixaban Management

The American Society of Anesthesiologists and other guideline societies recommend holding apixaban for at least 48 hours before a right heart catheterization procedure due to its high bleeding risk classification 1, 2

For patients with normal renal function, the European Society of Cardiology recommends discontinuing apixaban at least 48 hours before the procedure 1, 2
For patients with impaired renal function, consider extending the discontinuation period to at least 48 hours, with possible consideration for longer periods, as suggested by the National Comprehensive Cancer Network 2, 3

Right heart catheterization is classified as a high bleeding risk procedure due to the potential for vascular complications and cardiac perforation, according to the French Working Group on Perioperative Hemostasis guidelines 1, 4
The French Working Group on Perioperative Hemostasis guidelines specifically note that procedures with high bleeding risk require discontinuation of direct oral anticoagulants like apixaban for at least 48 hours 1, 4

Unlike dabigatran, apixaban has less renal dependence for clearance, as noted by the European Heart Journal 1, 2
However, in patients with severe renal impairment, drug accumulation may occur, and a longer discontinuation period may be warranted, according to the Journal of the National Comprehensive Cancer Network 3

For low bleeding risk after the procedure with adequate hemostasis, apixaban can be resumed at least 6 hours after the procedure, as recommended by the Anaesthesia journal 4
For high bleeding risk or concerns about hemostasis, delay resumption for 48-72 hours, as suggested by the European Heart Journal and Anaesthesia journal 1, 2

Unnecessary bridging with heparin products is not recommended for most patients on apixaban and may increase bleeding risk, according to the European Heart Journal and Anaesthesia journal 2, 4
Failing to adjust discontinuation timing based on renal function can lead to either excessive bleeding risk or unnecessary thrombotic risk, as noted by the European Heart Journal and Journal of the National Comprehensive Cancer Network 2, 3
Laboratory monitoring of anti-Xa activity is generally not required but may be considered in patients with severe renal dysfunction or other factors affecting drug clearance, as suggested by the Anaesthesia journal and Gut journal 1, 5